Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer-related constipation.

Jay Thomas1

  • 1San Diego Hospice & Palliative Care, San Diego, San Diego, CA 92103, USA. jathomas@ucsd.edu

Current Oncology Reports
|June 26, 2007
PubMed
Summary
This summary is machine-generated.

Cancer-related constipation significantly impacts patient quality of life. New targeted therapies, including investigational opioid antagonists, show promise for managing this condition, addressing a gap in current FDA-approved treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Thematic Exploration of the Experience of Inpatient Mental-Health Service-Users Who Are Prevented from Self-Harming.

Issues in mental health nursing·2025
Same author

The Expanded Evidence-Centered Design (e-ECD) for Learning and Assessment Systems: A Framework for Incorporating Learning Goals and Processes Within Assessment Design.

Frontiers in psychology·2019
Same author

Thermally induced amorphous to amorphous transition in hot-compressed silica glass.

The Journal of chemical physics·2018
Same author

Structure and Properties of Silica Glass Densified in Cold Compression and Hot Compression.

Scientific reports·2015
Same author

Interdisciplinary palliative care intervention in metastatic non-small-cell lung cancer.

Clinical lung cancer·2013
Same author

Spiritual care for Jewish patients facing a life-threatening illness.

Journal of palliative care·2013
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
Same journal

The Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves.

Current oncology reports·2026
See all related articles

Area of Science:

  • Gastroenterology
  • Oncology
  • Pharmacology

Background:

  • Cancer-related constipation is a prevalent issue negatively affecting patient quality of life.
  • The underlying causes and optimal therapeutic strategies for cancer-related constipation are not well understood.
  • Limited data exists on the efficacy of US Food and Drug Administration (FDA)-approved medications for this specific patient population.

Purpose of the Study:

  • To review current understanding and therapeutic options for cancer-related constipation.
  • To explore the potential role of newly FDA-approved agents and investigational drugs in managing this condition.

Main Methods:

  • Literature review of existing studies on cancer-related constipation.
  • Analysis of FDA-approved medications for chronic idiopathic constipation and their potential application.

Related Experiment Videos

  • Examination of preliminary data for investigational therapies, specifically peripherally acting opioid receptor antagonists.

    • Main Results:

    • Current treatments for cancer-related constipation are limited, with few comparative studies on laxative efficacy.
    • FDA-approved drugs like lubiprostone and tegaserod, initially for chronic idiopathic constipation, require further investigation for cancer patients.
    • Investigational agents, alvimopan and methylnaltrexone, show preliminary promise in managing cancer-related constipation.

    Conclusions:

    • There is a significant unmet need for effective therapies for cancer-related constipation.
    • Targeted therapies, including novel opioid receptor antagonists, may offer new avenues for treatment.
    • Further research is crucial to establish the efficacy and safety of these agents in cancer patients.